A new chapter is beginning for iPSCs: Qihan Biotech, a leading innovator in cell engineering, has reported the first clinical use of an induced pluripotent stem cell (iPSC)-derived CAR natural killer (NK) therapy in an autoimmune disease. The product, known as QN-139b, was administered to a patient with refractory systemic sclerosis (SSc), marking the first time an iPSC-derived CAR immune therapy has been used beyond oncology. [Read more…]
HeartBeat.bio and Boehringer Ingelheim Use Human iPSC-Based Cardioids to Model Inherited Cardiomyopathies
HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders
Vienna, Austria – September 23, 2025 – HeartBeat.bio has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. The partnership combines Boehringer Ingelheim’s expertise in gene therapy drug development with HeartBeat.bio’s proprietary Cardioid Drug Discovery Platform, aiming to advance innovative therapies for inherited heart muscle diseases. [Read more…]
uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells
GERMANTOWN, MD, September 17, 2025 – uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing technology development, announced the launch of its 2nd-Generation iPSC Reprogramming Kit, powered by proprietary RNA-LNP technology. The kit is designed and proven to deliver best-in-class performance to reprogram peripheral blood mononuclear cells (PBMCs) to induced pluripotent stem cell (iPSC). [Read more…]
Mytos Advances Automated iPSC Manufacturing through Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip
Mytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy Trials
Mytos’ iDEM platform replaces traditional iPSC manufacturing with a closed, automated system that delivers consistent, GMP-ready cells while reducing cost, variability, and time to clinic
Collaborations highlight the versatility of Mytos’ iDEM platform across diverse cell types and clinical applications from blindness and hearing loss to complex bone regeneration
Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research
LEIDEN, Netherlands — Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment, today announced the launch of Ncyte® NHP-C vCardiomyocytes, the first commercially available ventricular-like cardiomyocytes derived from induced pluripotent stem cells (iPSCs) of cynomolgus monkeys. New Ncyte® NHP-C vCardiomyocytes provide a scalable, ethical and translational tool for cross-species cardiac studies. [Read more…]
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 79
- Next Page »